Centric Wealth Management Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Centric Wealth Management purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,891 shares of the biopharmaceutical company's stock, valued at approximately $1,468,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. HHM Wealth Advisors LLC raised its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new position in Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC increased its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 302,785 shares of company stock valued at $30,503,250 in the last three months. Company insiders own 0.16% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have issued reports on GILD. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price target for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Bank of America lifted their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. DZ Bank raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Oppenheimer increased their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 4th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $5.14 during trading hours on Friday, reaching $107.25. The company had a trading volume of 12,918,179 shares, compared to its average volume of 7,351,764. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The firm has a market cap of $133.54 billion, a PE ratio of 289.86, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. The business has a fifty day simple moving average of $107.30 and a 200 day simple moving average of $95.89.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. Gilead Sciences's dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.